ArticleMolecular pharmaceutics
Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice.
Article in Molecular pharmaceutics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Liposomal DoxorubicinCurrent drug delivery · 2024Pooled it
- Exomeres and supermeres: Current advances and perspectives.Bioactive materials · 2025Review
- Targeted Liposomal Drug Delivery: Overview of the Current Applications and Challenges.Life (Basel, Switzerland) · 2024Review
- Peptides Targeting HER2-Positive Breast Cancer Cells and Applications in Tumor Imaging and Delivery of Chemotherapeutics.Nanomaterials (Basel, Switzerland) · 2023Review
- Targeted Delivery of Combination Therapeutics Using Monoclonal Antibody 2C5-Modified Immunoliposomes for Cancer Therapy.Pharmaceutical research · 2021Article
- Cetuximab Immunoliposomes Enhance Delivery of 5-FU to Skin Squamous Carcinoma Cells.Anti-cancer agents in medicinal chemistry · 2017Article
- Quantum dot-mediated delivery of siRNA to inhibit sphingomyelinase activities in brain-derived cells.Journal of neurochemistry · 2016Article
- Doxorubicin liposomes as an investigative model to study the skin permeation of nanocarriers.International journal of pharmaceutics · 2015Article
- Micelle-like nanoparticles as carriers for DNA and siRNA.Molecular pharmaceutics · 2015Review
- Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery.Nature reviews. Drug discovery · 2014Review
- Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models.Cancer biology & therapy · 2014Article
- Immunoconjugates and long circulating systems: origins, current state of the art and future directions.Advanced drug delivery reviews · 2013Review
- Challenges in development of targeted liposomal therapeutics.The AAPS journal · 2012Review
- Quantum dot loaded immunomicelles for tumor imaging.BMC medical imaging · 2010Article
- Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes.International journal of nanomedicine · 2010Article
- Stimulus-responsive macromolecules and nanoparticles for cancer drug delivery.Nanomedicine (London, England) · 2010Review
- Targeted Nanodelivery of Drugs and Diagnostics.Nano today · 2010Article
- Release of liposomal contents by cell-secreted matrix metalloproteinase-9.Bioconjugate chemistry · 2009Article
- Article
- Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery.Molecular pharmaceuticsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The efficacy of drug delivery systems can be significantly enhanced by making them target-specific via the attachment of various ligands to their surface. We attempted to enhance tumor accumulation and therapeutic effect of doxorubicin-loaded long-circulating liposomes (Doxil, ALZA Corp.) by coupling to their surface the anticancer monoclonal antibody 2C5 (mAb 2C5) with nuclesome (NS)-restricted activity, that can recognize the surface of various tumor but not normal cells via the surface-bound nucleosomes released from the apoptotically dying neighboring tumor cells and specifically targets pharmaceutical carriers to tumor cells in vitro and in vivo. Antibody coupling to PEGylated doxorubicin-liposomes was performed by the "post-insertion" technique. The pharmacokinetics of plain and immuno-targeted Doxil-mimicking liposomes, as well as their accumulation in primary Lewis lung carcinoma (LLC) tumors in mice was followed by real-time gamma-scintigraphy upon liposomal membrane labeling with (111)In. Therapeutic action of various liposomal formulations was followed by registering primary tumor growth, determining tumor weigh upon mice sacrifice, and by counting the number of metastases in the liver and lungs. 2C5 antibody-targeted liposomes demonstrate significantly enhanced accumulation in LLC tumors. Targeted doxorubicin-loaded PEG-liposomes were significantly more effective in inhibiting tumor growth and metastatic process in the LLC tumor models in mice. Our results clearly show the remarkable capability of 2C5-targeted Doxil to specifically deliver its cargo into various tumor manifestations (solid and metastatic) significantly increasing the efficacy of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.